zepbound tirzepatide - Search News

News

Zepbound beats Wegovy for weight loss

The Associated Press on MSN · 22h

Battle of the weight loss blockbuster drugs: Zepbound beats Wegovy by nearly 50%

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks. Those who took semaglutide — known as Novo Nordisk's Wegovy, lost about 33 pounds.

HealthLeaders Media · 22m

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

CBS News · 22h

Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

Applied Clinical Trials Online22h

Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results